Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2022-01-07 Investor Presentation
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Investor Presentation Classification · 85% confidence The document is a press release announcing that Medexus Pharmaceuticals' CEO and CFO will present at the H.C. Wainwright BioConnect 2022 Conference. It includes details about the presentation availability and company background but does not contain any financial results, detailed financial data, or regulatory filings. It is an announcement of an investor presentation event rather than the presentation itself or a financial report. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length is short and does not contain actual financial statements or analysis, confirming it is an announcement of a presentation rather than the presentation report itself, but given the options, IP is the closest fit as it relates to investor-focused presentation content.
2022-01-07 English
News release - English.pdf
Regulatory Filings
2021-12-02 English
News release - English.pdf
Regulatory Filings
2021-12-02 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements (unaudited)' for the three- and six-month periods ended September 30, 2021. It contains detailed financial statements including Statements of Financial Position, Income, Changes in Shareholders' Equity, and Cash Flows, along with notes explaining accounting policies and other relevant information. The document explicitly states it is prepared in accordance with IFRS IAS 34, which governs interim financial reporting. The presence of actual financial data and comprehensive financial analysis for a period shorter than a full fiscal year confirms this is an Interim / Quarterly Report. The document length (15,000 characters) and content confirm it is the report itself, not an announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2022
2021-11-11 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Board/Management Information Classification · 100% confidence The document announces the appointment of Dr. Peter Hancock to the company's Board of Directors. It focuses on management changes and does not contain financial data, report attachments, or voting results. The content fits the category of Board/Management Information, which covers announcements of changes in the company's board or senior management.
2021-11-10 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2021. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3395 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-11-10 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.